Related Experiment Videos
Lipoprotein-X: a substrate for lecithin: cholesterol acyltransferase.
European Journal of Clinical Investigation
|June 1, 1977
Summary
Lecithin:cholesterol acyltransferase (LCAT) can modify abnormal lipoproteins (LP-X) found in obstructive liver disease. This study shows LP-X acts as a substrate for LCAT, forming new cholesteryl esters.
Area of Science:
- Lipid metabolism
- Biochemistry
- Clinical chemistry
Background:
- Abnormal lipoproteins, such as LP-X, accumulate in plasma during obstructive liver disease.
- The enzyme lecithin:cholesterol acyltransferase (LCAT) plays a crucial role in plasma lipid metabolism.
Purpose of the Study:
- To investigate the interaction between LCAT and LP-X.
- To determine if LP-X can serve as a substrate for LCAT.
Main Methods:
- Isolation and purification of LP-X from patient plasma.
- Incubation of labeled LP-X with purified LCAT enzyme.
- Analysis of reaction products using zonal ultracentrifugation and agarose electrophoresis.
Main Results:
- LCAT catalyzed the formation of cholesteryl esters from cholesterol within LP-X.
- LP-X underwent electrophoretic changes, indicating structural modification.
- Lipoprotein size distribution remained largely unchanged after incubation.
Conclusions:
- LP-X is a functional substrate for LCAT.
- LCAT activity contributes to the modification of abnormal lipoproteins in liver disease.